{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:50:14Z","timestamp":1790419814785,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2016 n\u00ba1684"],"award-info":[{"award-number":["2016 n\u00ba1684"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01373","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T05:11:51Z","timestamp":1560489111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":66,"title":["Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms"],"prefix":"10.3389","volume":"10","author":[{"given":"Cecilia P.","family":"Marin Oyarz\u00fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula G.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-2006-939431","article-title":"Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status","volume":"77","author":"Heller","year":"2006","journal-title":"Eur J Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica."},{"key":"B11","doi-asserted-by":"publisher","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1182\/blood-2016-10-746479","article-title":"Elevated hematocrit enhances platelet accumulation following vascular injury","volume":"129","author":"Walton","year":"2017","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood."},{"key":"B17","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cyto.2010.04.011","article-title":"Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms","volume":"51","author":"Goette","year":"2010","journal-title":"Cytokine."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ejh.12614","article-title":"Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2\/CALR\/MPL mutational status","volume":"96","author":"Mela Osorio","year":"2016","journal-title":"Eur J Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon \u03b1-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol."},{"key":"B30","first-page":"448","article-title":"Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide","volume":"60","author":"Laguna","year":"2000","journal-title":"Medicina."},{"key":"B31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00277-007-0386-3","article-title":"Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis","volume":"87","author":"Alvarez-Larr\u00e1n","year":"2008","journal-title":"Ann Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ajh.10091","article-title":"Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide","volume":"70","author":"Lev","year":"2002","journal-title":"Am J Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"van Genderen","year":"1996","journal-title":"Thromb Haemost."},{"key":"B34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1042\/bj3160093","article-title":"Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation","volume":"316","author":"Rodriguez-Linares","year":"1996","journal-title":"Biochem J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","article-title":"JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients","volume":"118","author":"Panova-Noeva","year":"2011","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/jth.12965","article-title":"Regulation of the genetic code in megakaryocytes and platelets","volume":"13","author":"Rondina","year":"2015","journal-title":"J Thromb Haemost."},{"key":"B37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41408-017-0010-2","article-title":"CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles","volume":"7","author":"Zini","year":"2017","journal-title":"Blood Cancer J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","article-title":"Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders","volume":"110","author":"Jensen","year":"2000","journal-title":"Br J Haematol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood-2012-05-431288","article-title":"Dysfunction of the PI3 kinase\/Rap1\/integrin \u03b1(IIb)\u03b2(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia","volume":"121","author":"Moore","year":"2013","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1582-4934.2001.tb00140.x","article-title":"Abnormalities of platelet aggregation in chronic myeloproliferative disorders","volume":"5","author":"Avram","year":"2001","journal-title":"J Cell Mol Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/09537100802691544","article-title":"In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?","volume":"20","author":"Grignani","year":"2009","journal-title":"Platelets."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09537104.2019.1584668","article-title":"Evaluation of platelet function in essential thrombocythemia under different analytical conditions","author":"Lussana","year":"2019","journal-title":"Platelets."},{"key":"B43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"B44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3324\/haematol.2012.082560","article-title":"Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation","volume":"98","author":"Hurtado-Nedelec","year":"2013","journal-title":"Haematologica."},{"key":"B46","doi-asserted-by":"publisher","first-page":"38738","DOI":"10.1038\/srep38738","article-title":"Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms","volume":"6","author":"Marin","year":"2016","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3324\/haematol.2016.142471","article-title":"Propagation of thrombosis by neutrophils and extracellular nucleosome networks","volume":"102","author":"Pfeiler","year":"2017","journal-title":"Haematologica."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8767","DOI":"10.1073\/pnas.91.19.8767","article-title":"P-selectin induces the expression of tissue factor on monocytes","volume":"91","author":"Celi","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1172\/JCI118575","article-title":"Activated platelets signal chemokine synthesis by human monocytes","volume":"97","author":"Weyrich","year":"1996","journal-title":"J Clin Invest."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","author":"Fisher","year":"2019","journal-title":"Leukemia."},{"key":"B51","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","article-title":"Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation","volume":"121","author":"Rosti","year":"2013","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb Haemost."},{"key":"B54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica."},{"key":"B55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ajh.21974","article-title":"Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Panova-Noeva","year":"2011","journal-title":"Am J Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"Trappenburg","year":"2009","journal-title":"Haematologica."},{"key":"B58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2018.03.024","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell."},{"key":"B59","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/ATVBAHA.113.302700","article-title":"Interleukin 1 receptor 1 and interleukin 1\u03b2 regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans","volume":"34","author":"Beaulieu","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.leukres.2014.07.006","article-title":"The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?","volume":"38","author":"Hasselbalch","year":"2014","journal-title":"Leuk Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.13539","article-title":"Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation","volume":"172","author":"Torregrosa","year":"2016","journal-title":"Br J Haematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.3324\/haematol.2016.144279","article-title":"Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia","volume":"101","author":"Charpentier","year":"2016","journal-title":"Haematologica."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1111\/j.1538-7836.2006.02194.x","article-title":"Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?","volume":"4","author":"Maugeri","year":"2006","journal-title":"J Thromb Haemost."},{"key":"B66","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.3324\/haematol.2015.128918","article-title":"The effects of JAK inhibitor therapy upon novel markers of thrombosis in myeloproliferative neoplasms","volume":"100","author":"Keohane","year":"2015","journal-title":"Haematologica."},{"key":"B68","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjh.15682","article-title":"Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis","volume":"185","author":"Barone","year":"2018","journal-title":"Br J Haematol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"9","author":"Tefferi","year":"2019","journal-title":"Am J Hematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica."},{"key":"B72","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?","volume":"30","author":"Hasselbalch","year":"2006","journal-title":"Leuk Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:25:25Z","timestamp":1574965525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2019.01373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"article-number":"1373"}}